Policy initiatives and growing demand for testosterone therapy have converged with a medical debate about who truly benefits from hormone replacement, and how patients are being diagnosed. Recent reporting shows the Pentagon is preparing to screen service members for low testosterone while federal officials are considering loosening rules on who may receive treatment.
What the evidence shows — and what it does not
Clinical trials indicate testosterone replacement can help men with a clear deficiency, but large questions remain about broader use. The TRAVERSE trial, published in 2023 in the New England Journal of Medicine, followed middle-aged and older men using testosterone gel and found no increase in heart attack or stroke compared with placebo when hormone levels were maintained within a normal range. However, the trial also reported a higher risk of bone fractures, underlining that perceived safety is relative.
Experts cited in recent coverage emphasise that benefits appear concentrated in men with unequivocally low testosterone. As one endocrinologist warned, the lower the baseline testosterone, the more likely benefits are to be seen. Another clinician stressed that testosterone is intended to restore normal physiology in men with a genuine deficiency rather than to serve as a ‘‘fountain of youth’’. Those comments make a clear distinction between marketing narratives and the medical indication for therapy.
“The goal of testosterone therapy isn’t peak performance. It is restoring normal physiology in men who have a true deficiency,” said Dr Helen Bernie, director of Sexual and Reproductive Medicine at Indiana University, as reported.
Diagnosis, not the drug, is the central problem
Much of the current controversy centres on how low testosterone is diagnosed. A 2022 study published in JAMA Internal Medicine used secret shoppers with normal testosterone levels who visited direct-to-consumer clinics; most were prescribed testosterone despite normal laboratory results. That finding raises concern that broadening eligibility without improving diagnostic standards and oversight could lead to many men receiving treatment they do not need.
- Demand drivers: growing public interest, advertisements and clinics on social platforms.
- Policy signals: moves by the Pentagon to screen military personnel and proposals to loosen federal eligibility.
- Clinical evidence: trials support benefit in clearly deficient men but show some risks.
Potential consequences of looser rules
If regulators widen criteria without strengthening how patients are assessed, men who are not truly deficient could be started on long-term therapy. That raises several concerns: exposure to adverse effects (the TRAVERSE trial’s fracture signal is one example), the medicalisation of age-related symptoms such as fatigue or reduced libido, and the diversion of care from patients with documented need.
| Issue | Evidence / Concern |
|---|---|
| Cardiovascular safety | TRAVERSE: no increase in heart attack or stroke when levels kept in normal range |
| Bone health | TRAVERSE: higher risk of bone fractures observed |
| Diagnosis quality | JAMA study: many prescriptions issued despite normal testosterone levels |
What patients and clinicians should consider
Clinicians and patients should separate marketing from medicine. For men experiencing symptoms that might prompt consideration of testosterone, the following steps are prudent:
- Confirm symptoms with a thorough clinical assessment and use reliable laboratory testing.
- Reserve therapy for those with consistently low measured testosterone and correlated clinical features.
- Discuss potential harms and monitor patients on treatment, adjusting doses to keep levels within a normal range.
Public interest and policy shifts will likely keep testosterone therapy in the headlines. Moving forward, regulatory decisions that broaden access should be paired with clear diagnostic standards and oversight of clinics that prescribe hormone therapy. That pairing would help ensure the treatment remains targeted to those most likely to benefit, limiting unnecessary exposure among men for whom evidence of benefit is weak or absent.
